DT&CRO Co (XKRX:383930) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is DT&CRO Co Debt-to-Equity?

DT&CRO Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0 Mil. DT&CRO Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0 Mil. DT&CRO Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩27,069 Mil. DT&CRO Co's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for DT&CRO Co's Debt-to-Equity or its related term are showing as below:

XKRX:383930' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.11 Med: 0.25 Max: 0.5
Current: 0.59

During the past 4 years, the highest Debt-to-Equity Ratio of DT&CRO Co was 0.50. The lowest was 0.11. And the median was 0.25.

XKRX:383930's Debt-to-Equity is ranked worse than
77.62% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs XKRX:383930: 0.59

DT&CRO Co Debt-to-Equity Historical Data

The historical data trend for DT&CRO Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DT&CRO Co Debt-to-Equity Chart

DT&CRO Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.78

0.27

0.11

0.50

DT&CRO Co Quarterly Data
	Jun21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial					0.17	0.28	0.31	0.50	-

Competitive Comparison of DT&CRO Co's Debt-to-Equity

For the Biotechnology subindustry, DT&CRO Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DT&CRO Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DT&CRO Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where DT&CRO Co's Debt-to-Equity falls into.

DT&CRO Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

DT&CRO Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3577.288	+	12303.275)	/	31678.923
	=	0.50

DT&CRO Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	27068.852
	=	0.00

DT&CRO Co (XKRX:383930) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

DT&CRO Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of DT&CRO Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

DT&CRO Co (XKRX:383930) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DT&CRO Co Ltd (XKRX:383930) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

28, Baengnyeong-ro 20beon-gil, 2nd, 3rd, 4th floor, Na-dong, Cheoin-gu, Gyeonggi-do (Yubang-dong), Yongin-si, KOR, 17042

Website

http://www.dtncro.com

DT&CRO Co Ltd conducts a series of consigned research, from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics and medical devices, to analysis, bioactivity, clinical trials, and licensing consulting. provided as a service.

DT&CRO Co (XKRX:383930) Headlines

No Headlines